Cite
MLA Citation
Z.A. Wainberg et al.. “317 Safety and efficacy results from a phase 1 dose-escalation trial of the parp inhibitor talazoparib (bmn-673) in combination with either temozolomide or irinotecan in patients with advanced malignancies.” European journal of cancer, vol. 51, n.d., pp. S60–. http://access.bl.uk/ark:/81055/vdc_100030627995.0x000046